Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 189

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 189
---
,498 4.10$58.54 191,316 $58.32 $64.65-$68.74312,067 5.12$67.47 245,199 $67.67 $69.39-$73.76233,288 7.66$70.78 125,319 $71.02 $73.92-$75.09288,134 7.73$74.76 105,797 $74.88 $78.56-$88.27155,478 8.57$82.22 32,249 $81.71 $89.20-$89.20444,229 8.35$89.20 103,190 $89.20 $89.86-$103.42244,385 4.64$98.53 218,106 $98.24 $104.30-$114.1528,290 6.73$110.98 12,966 $114.15 $122.70-$122.7010,260 9.92$122.70 — $— 2,226,273 6.58$75.14 1,229,294 $72.15 The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted: Year Ended December 31, 202420232022Risk-free interest rate3.5%-4.5%3.7%-4.6%1.4%-4.3%Expected volatility44%-46%45%-54%49%-55%Expected term4.1 to 4.8 years4.7 to 5.3 years2.0 to 6.5 yearsAs of December 31, 2024, there was $34.0 million of total unrecognized compensation cost related to non-vested stock options under the 2002 Plan. That cost is expected to be recognized over a weighted average period of 2.5 years.As of December 31, 2024, there was $0.1 million of total unrecognized compensation cost related to non-vested OmniAb stock options received in connection with the OmniAb Transactions described above. That cost is expected to be recognized over a weighted average period of 0.5 years.Restricted Stock ActivityThe following is a summary of our restricted stock activity and